Targeting DNA Repair Defects for Precision Medicine in Prostate Cancer.
Androgen receptor
BRCA1/2
DNA damage repair
Genomic alterations
PARP
Personalized medicine
Prostate cancer
Journal
Current oncology reports
ISSN: 1534-6269
Titre abrégé: Curr Oncol Rep
Pays: United States
ID NLM: 100888967
Informations de publication
Date de publication:
27 03 2019
27 03 2019
Historique:
entrez:
29
3
2019
pubmed:
29
3
2019
medline:
1
8
2020
Statut:
epublish
Résumé
Genomic studies of localized and metastatic prostate cancer have identified a high prevalence of clinically actionable alterations including mutations in DNA repair genes. In this manuscript, we review the current knowledge on DNA repair defects in prostate cancer and provide an overview of how these alterations can be targeted towards a personalized prostate cancer management. Twenty to 25% of metastatic prostate cancers harbor defects in DNA repair genes, most commonly in the homologous recombination genes. These defects confer increased sensitivity to platinum chemotherapy or poly (ADP-ribose) polymerase (PARP) inhibitors. Recent trials also support a synergistic effect of combining these therapies with androgen receptor-targeting agents. Identification of mismatch-repair defects could result in defining a prostate cancer population who may benefit from immune checkpoint inhibitors. These data have implications for family testing and early diagnosis, as many of these mutations are linked to inherited risk of prostate cancer. The DNA damage repair pathways are clinically relevant in prostate cancer, being a target for precision medicine; combination with standard-of-care androgen receptor (AR)-targeting agents may be synergistic.
Identifiants
pubmed: 30919167
doi: 10.1007/s11912-019-0790-6
pii: 10.1007/s11912-019-0790-6
doi:
Substances chimiques
AR protein, human
0
Antineoplastic Agents, Immunological
0
Poly(ADP-ribose) Polymerase Inhibitors
0
Receptors, Androgen
0
Platinum
49DFR088MY
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
42Références
Am J Hum Genet. 2003 Jan;72(1):1-12
pubmed: 12474142
Nature. 2005 Apr 14;434(7035):913-7
pubmed: 15829966
Nature. 2005 Apr 14;434(7035):917-21
pubmed: 15829967
Cell Res. 2008 Jan;18(1):99-113
pubmed: 18166982
N Engl J Med. 2009 Jul 9;361(2):123-34
pubmed: 19553641
J Clin Oncol. 2010 Feb 20;28(6):1061-8
pubmed: 20100962
Lancet. 2010 Jul 24;376(9737):235-44
pubmed: 20609467
Mol Cell. 2010 Oct 22;40(2):179-204
pubmed: 20965415
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Cancer Cell. 2011 May 17;19(5):664-78
pubmed: 21575865
Nat Struct Mol Biol. 2011 Jul 06;18(7):748-54
pubmed: 21731065
Br J Cancer. 2011 Oct 11;105(8):1230-4
pubmed: 21952622
N Engl J Med. 2012 Apr 12;366(15):1382-92
pubmed: 22452356
Nature. 2012 Jul 12;487(7406):239-43
pubmed: 22722839
Eur Urol. 2013 May;63(5):920-6
pubmed: 22981675
Cancer Discov. 2012 Dec;2(12):1134-49
pubmed: 22993403
J Clin Oncol. 2013 May 10;31(14):1748-57
pubmed: 23569316
Clin Cancer Res. 2013 Jul 1;19(13):3621-30
pubmed: 23649003
Lancet Oncol. 2013 Aug;14(9):882-92
pubmed: 23810788
Clin Cancer Res. 2013 Oct 1;19(19):5485-93
pubmed: 23922302
Nature. 2013 Aug 22;500(7463):415-21
pubmed: 23945592
Cancer Discov. 2013 Nov;3(11):1245-53
pubmed: 24027196
Cancer Discov. 2013 Nov;3(11):1254-71
pubmed: 24027197
Mol Cell Biol. 2014 Apr;34(8):1380-8
pubmed: 24469398
Br J Cancer. 2014 Mar 18;110(6):1663-72
pubmed: 24556621
Oncogene. 2015 May 28;34(22):2815-22
pubmed: 25132269
Nat Commun. 2014 Sep 25;5:4988
pubmed: 25255306
J Clin Oncol. 2015 Jan 20;33(3):244-50
pubmed: 25366685
Nature. 2014 Nov 27;515(7528):577-81
pubmed: 25428507
Eur Urol. 2015 Aug;68(2):186-93
pubmed: 25454609
Cell. 2015 May 21;161(5):1215-1228
pubmed: 26000489
N Engl J Med. 2015 Jun 25;372(26):2509-20
pubmed: 26028255
Science. 2015 Oct 9;350(6257):207-211
pubmed: 26359337
N Engl J Med. 2015 Oct 29;373(18):1697-708
pubmed: 26510020
Cell. 2015 Nov 5;163(4):1011-25
pubmed: 26544944
Eur Urol. 2016 Jun;69(6):992-5
pubmed: 26724258
Nat Med. 2016 Apr;22(4):369-78
pubmed: 26928463
Oncotarget. 2016 Aug 16;7(33):52810-52817
pubmed: 27429197
N Engl J Med. 2016 Aug 4;375(5):443-53
pubmed: 27433846
N Engl J Med. 2016 Dec;375(22):2154-2164
pubmed: 27717299
Lancet Oncol. 2017 Jan;18(1):75-87
pubmed: 27908594
Eur Urol. 2017 May;71(5):740-747
pubmed: 27989354
Cancer Discov. 2017 Jan;7(1):20-37
pubmed: 28003236
Cancer Discov. 2017 Jun;7(6):620-629
pubmed: 28242752
Eur Urol. 2017 Jul;72(1):34-42
pubmed: 28259476
Cancer Discov. 2017 Sep;7(9):1006-1017
pubmed: 28450425
Nat Med. 2017 Jun;23(6):703-713
pubmed: 28481359
Sci Signal. 2017 May 23;10(480):
pubmed: 28536297
N Engl J Med. 2017 Aug 10;377(6):523-533
pubmed: 28578601
N Engl J Med. 2017 Jul 27;377(4):352-360
pubmed: 28578607
Science. 2017 Jul 28;357(6349):409-413
pubmed: 28596308
Cancer Res. 2017 Sep 15;77(18):4745-4754
pubmed: 28754673
JCO Precis Oncol. 2017 Jul;2017:
pubmed: 28825054
Nat Commun. 2017 Aug 29;8(1):374
pubmed: 28851861
Mutat Res. 2017 Jul;773:174-187
pubmed: 28927527
Cancer Discov. 2018 Apr;8(4):444-457
pubmed: 29367197
Eur Urol. 2018 May;73(5):687-693
pubmed: 29429804
Eur Urol. 2018 Aug;74(2):218-225
pubmed: 29439820
Cold Spring Harb Perspect Med. 2019 Jan 2;9(1):null
pubmed: 29530944
J Biol Chem. 2018 Jul 6;293(27):10524-10535
pubmed: 29599286
Nat Genet. 2018 May;50(5):645-651
pubmed: 29610475
J Clin Oncol. 2018 May 20;36(15):1498-1504
pubmed: 29624463
Ann Oncol. 2018 May 1;29(5):1203-1210
pubmed: 29635390
J Clin Invest. 2018 Jul 2;128(7):2979-2995
pubmed: 29863497
Lancet Oncol. 2018 Jul;19(7):975-986
pubmed: 29880291
Cell. 2018 Jun 14;173(7):1770-1782.e14
pubmed: 29906450
N Engl J Med. 2018 Jun 28;378(26):2465-2474
pubmed: 29949494
Ann Oncol. 2018 Aug 1;29(8):1807-1813
pubmed: 29992241
Cell. 2018 Jul 26;174(3):758-769.e9
pubmed: 30033370
Nat Genet. 2018 Sep;50(9):1262-1270
pubmed: 30104763
Eur Urol. 2019 May;75(5):743-749
pubmed: 30309687
Eur Urol. 2019 Mar;75(3):378-382
pubmed: 30337059
Eur Urol. 2019 Jan;75(1):184-192
pubmed: 30340782
N Engl J Med. 2018 Dec 27;379(26):2495-2505
pubmed: 30345884
EMBO Mol Med. 2018 Dec;10(12):
pubmed: 30377213
EMBO Mol Med. 2018 Dec;10(12):
pubmed: 30467127
JAMA Oncol. 2018 Dec 27;:null
pubmed: 30589920
J Clin Oncol. 2019 Feb 20;37(6):490-503
pubmed: 30625039